Brainsway Receives CE Approvals for Treating Multiple Sclerosis (MS), Stroke and Obsessive Compulsive Disorder (OCD) | Shavit Capital

Skip to content

About Us
Investment Focus
Team
Portfolio
News
Contact Us

Brainsway Receives CE Approvals for Treating Multiple Sclerosis (MS), Stroke and Obsessive Compulsive Disorder (OCD)

Brainsway Receives CE Approvals for Treating Multiple Sclerosis (MS), Stroke and Obsessive Compulsive Disorder (OCD)